India, June 9 -- Palvella Therapeutics Inc. (PVLA), a clinical-stage biopharmaceutical company, Monday it has received the initial proceeds from a previously announced grant from the FDA Office of Orphan Products Development.
The grant supports the company's ongoing Phase 3 SELVA trial of Qtorin 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations.
Out of 51 applications received by the FDA Orphan Products Grants Program in fiscal year 2024, Palvella's Phase 3 Selva trial was one of only seven new clinical trials selected for funding-and the only Phase 3 trial awarded.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
The Selva trial is a 24-week, Phase 3, single-arm, b...